RESEARCH MONOGRAPH · KDC-MN-175

Kanna (Sceletium tortuosum)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

67/100

Mesembrine and the SSRI-like alkaloids make this genuinely interesting, even with thin clinical data

Sceletium tortuosum is one of the more pharmacologically interesting traditional botanicals around right now, partly because the active alkaloid fraction (mesembrine, mesembrenone, mesembrenol, tortuosamine) actually has a mappable mechanism that mostly aligns with what users report, which is rare in the traditional-botanical space.

Mesembrine is the most-studied alkaloid in the fraction, and it's a fairly selective serotonin reuptake inhibitor in vitro, with affinity at SERT that's competitive with some clinical SSRIs in receptor binding studies. Mesembrenone adds PDE4 inhibition to the mix, which is a different mechanism with implications for mood and cognition. So unlike most traditional plants, you can actually trace the reported anxiolytic and mood-lifting effects to specific receptor-level pharmacology.

Clinical data is sparse but suggestive. Zembrin is the standardized extract that's been used in most of the published human work (developed by HG&H Pharmaceuticals, standardized to a specific alkaloid profile, low mesembrine, higher mesembrenone). Two or three small RCTs at 25-50mg Zembrin have shown anxiolytic effects, some cognitive performance signal under stress, and acceptable safety. The Brain Behaviour Research Group at Mt Royal in South Africa has been the most active research group on this.

The chemotype-and-standardization issue is enormous here. Wild Sceletium varies dramatically in alkaloid content and ratio. Traditional fermented preparations (kougoed) have different chemistry from fresh or simply-dried material. Zembrin-quality standardized extracts cost more but actually correspond to what the clinical literature studied. Random bulk Sceletium powder from unspecified sources is a mystery box.

Sourcing-wise the legitimate Zembrin material is well-characterized. Other vendor sources vary widely. HPLC verification of alkaloid profile is available but most commercial vendors dont disclose it.

Safety profile from the studied material looks clean. There's a theoretical serotonergic interaction concern with SSRIs and MAO inhibitors that has not been observed clinically but is mechanistically plausible.

What we like: the SSRI/PDE4 dual mechanism is genuinely interesting, the clinical signal is real, and this is one of the more credible traditional-medicine to modern-pharmacology translations we have. What we dont like: the wild variability in non-standardized material, and the way the supplement market markets non-Zembrin Sceletium with claims that only Zembrin actually supports.

Evidence: 60
Mechanism: 75
Reliability: 65
Safety: 72
Sourcing: 60
Value: 65
Signal: 72
Staying power: 68

Plain-language summary Intrigue 58 / 100

Kanna (Sceletium tortuosum) is a South African succulent traditionally fermented and chewed for mood and stress effects. The mesembrine alkaloids inhibit serotonin reuptake similar to SSRIs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

South African botanical / SSRI-like alkaloids

A South African succulent containing mesembrine alkaloids with serotonin reuptake inhibition and PDE4 inhibition activities.

Abstract

Kanna (Sceletium tortuosum) is a succulent native to South Africa with traditional use for mood elevation and anxiety. Active constituents are mesembrine alkaloids (mesembrine, mesembrenone, mesembrenol). Pharmacology includes serotonin reuptake inhibition (mesembrine has SSRI-like activity) and phosphodiesterase 4 (PDE4) inhibition (mesembrenone), the latter providing anti-inflammatory and modest cognitive effects through cAMP elevation. The compound has been formulated as standardized extracts (Zembrin) and studied in small Phase 2 trials for anxiety with positive but modest results. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

Mesembrine: serotonin reuptake inhibition. Mesembrenone: PDE4 inhibition with cAMP elevation.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Nell H, et al. A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. J Altern Complement Med 2013.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-175

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Kanna (Sceletium tortuosum)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs